ReviewCureus2026
Galectin-3 Beyond Conventional Cardiac Biomarkers and Its Incremental Prognostic Value in Heart Failure: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a heterogeneous clinical syndrome in which accurate risk stratification remains challenging despite the widespread use of natriuretic peptides and cardiac troponins. Galectin-3, a biomarker of inflammation and myocardial fibrosis, has emerged as a potential complementary prognostic marker; however, its incremental value beyond established biomarkers remains incompletely defined. This systematic review synthesizes primary clinical evidence evaluating the prognostic role of galectin-3 in adult heart failure populations, with a specific focus on its additive value beyond conventional cardiac biomarkers. A comprehensive literature search identified seven high-quality primary studies encompassing community-based cohorts, ambulatory chronic heart failure, heart failure with preserved ejection fraction, acute decompensated heart failure, and post-discharge populations. Across these studies, galectin-3 demonstrated incremental prognostic value for adverse outcomes, including mortality and heart failure-related hospitalization, particularly in fibrosis-dominant phenotypes such as heart failure with preserved ejection fraction and acute or recently decompensated heart failure. In contrast, its prognostic utility was attenuated in well-treated ambulatory patients with chronic heart failure with reduced ejection fraction after adjustment for natriuretic peptides. Importantly, studies incorporating serial galectin-3 measurements consistently demonstrated stronger associations with adverse outcomes than single baseline assessments, highlighting the value of longitudinal biomarker evaluation. Overall, the available evidence supports a phenotype-specific and dynamic role for galectin-3 as a complementary prognostic biomarker that reflects myocardial remodeling rather than hemodynamic stress alone. These findings refine the clinical positioning of galectin-3 and underscore its potential utility in risk stratification and disease monitoring, while emphasizing the need for prospective studies to evaluate galectin-3-guided management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.